Top

European Archives of Oto-Rhino-Laryngology

Published in:

29-12-2023 | Eosinophilia | Rhinology

Temporal trends of blood eosinophilia in severe uncontrolled CRSwNP treated with dupilumab: a real-life study

Authors: Eugenio De Corso, Claudio Montuori, Silvia Baroni, Rodolfo F. Mastrapasqua, Davide P. Porru, Leandro M. D’Auria, Giuseppe D’Agostino, Daniele Penazzi, Gabriele De Maio, Maria E. Onori, Francesca Sarlo, Marco Corbo’, Jacopo Galli

Published in: European Archives of Oto-Rhino-Laryngology | Issue 5/2024

Abstract

Purpose

Induced eosinophilia is commonly related to dupilumab treatment. We analysed the temporal trends of blood eosinophilia in patients with severe uncontrolled CRSwNP during the first year of treatment with dupilumab in real-life setting to evaluate its correlation with outcomes of response and adverse events (AEs).

Methods

Seventy-four patients with severe uncontrolled CRSwNP treated with dupilumab at our institution were enrolled. At each visit, we evaluated AEC, outcomes of response to treatment and AEs.

Results

A significant increase in AEC was observed since the first month with a peak at 3 months; at 12 months, the values returned comparable to those at baseline. A ≥ 50% increase of the baseline AEC with a value greater than 500 cells/mm³ was documented in 38/74 patients (Group A) regardless of the time of observation, whereas in 36/74 patients (Group B), no changes were observed. Analysing the blood eosinophilia trend over time in group A, we observed a temporary eosinophilia with early onset (within 6 months), persistent eosinophilia with early onset, and eosinophilia with late onset. No differences in terms of outcomes of response to treatment or AEs were found between Group A and Group B, or between patients who developed an AEC ≥ 1500 cells/mm³ or not.

Conclusion

In our series, we observed that an increase in AEC with different temporal trends may be observed in CRSwNP patients during the first year of treatment with dupilumab. In our series, eosinophilia is not correlated with a negative outcome of response to treatment or a risk of AEs.

Fokkens WJ, Lund VJ, Hopkins C, Hellings PW, Kern R, Reitsma S (2020) European position paper on rhinosinusitis and nasal polyps 2020. Rhinology 58(Suppl 29):1–464. https://doi.org/10.4193/Rhin20.600CrossRefPubMed

Fokkens WJ, Viskens AS, Backer V, Conti D, De Corso E, Gevaert P et al (2023) EPOS/EUFOREA update on indication and evaluation of Biologics in Chronic Rhinosinusitis with Nasal Polyps 2023. Rhinology 61(3):194–202. https://doi.org/10.4193/Rhin22.489CrossRefPubMed

De Corso E, Bellocchi G, De Benedetto M, Lombardo N, Macchi A, Malvezzi L et al (2022) Biologics for severe uncontrolled chronic rhinosinusitis with nasal polyps: a change management approach. Consensus of the Joint Committee of Italian Society of Otorhinolaryngology on biologics in rhinology. Acta Otorhinolaryngol Ital 42(1):1–16. https://doi.org/10.14639/0392-100X-N1614CrossRefPubMed

Bachert C, Mannent L, Naclerio RM, Mullol J, Ferguson BJ, Gevaert P et al (2016) Effect of subcutaneous dupilumab on nasal polyp burden in patients with chronic sinusitis and nasal polyposis. JAMA 315(5):469CrossRefPubMed

Bachert C, Han JK, Desrosiers M, Hellings PW, Amin N, Lee SE et al (2019) Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials. The Lancet 394(10209):1638–1650. https://doi.org/10.1001/jama.2015.19330CrossRef

De Corso E, Settimi S, Montuori C, Corbò M, Passali GC, Porru D et al (2022) Effectiveness of dupilumab in the treatment of patients with severe uncontrolled CRSwNP: a “real-life” observational study in the first year of treatment. JCM 11(10):2684. https://doi.org/10.3390/jcm11102684CrossRefPubMedPubMedCentral

Cantone E, De Corso E, Ricciardiello F, Di Nola C, Grimaldi G, Allocca V et al (2022) Olfaction recovery following dupilumab is independent of nasal polyp reduction in CRSwNP. JPM 12(8):1215. https://doi.org/10.3390/jpm12081215CrossRefPubMedPubMedCentral

Otten J, van der Lans R, De Corso E, Dziadziulia K, Hilvering B, Weersink E et al (2023) Evaluation of switching or simultaneous use of biologic treatment in patients with severe chronic rhinosinusitis with nasal polyps and severe asthma. Considerations in clinical decision making. Expert Rev Clin Immunol 29:1–9. https://doi.org/10.1080/1744666X.2023.2218617CrossRef

van der Lans RJL, Fokkens WJ, Adriaensen GFJPM, Hoven DR, Drubbel JJ, Reitsma S (2022) Real-life observational cohort verifies high efficacy of dupilumab for chronic rhinosinusitis with nasal polyps. Allergy 77(2):670–674. https://doi.org/10.1111/all.15134CrossRefPubMed

10.

De Corso E, Pipolo C, Cantone E, Ottaviano G, Gallo S, Trimarchi M et al (2023) Practical recommendations for managing severe chronic rhinosinusitis with nasal polyps in the era of biologics. Acta Otorhinolaryngol Ital. https://doi.org/10.14639/0392-100X-N2422CrossRefPubMedPubMedCentral

11.

De Corso E, Pasquini E, Trimarchi M, La Mantia I, Pagella F, Ottaviano G et al (2023) Dupilumab in the treatment of severe uncontrolled chronic rhinosinusitis with nasal polyps (CRSwNP): a multicentric observational phase IV real-life study (DUPIREAL). Allergy. https://doi.org/10.1111/all.15772CrossRefPubMed

12.

Castro M, Corren J, Pavord ID, Maspero J, Wenzel S, Rabe KF et al (2018) Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma. N Engl J Med 378(26):2486–2496. https://doi.org/10.1056/NEJMoa1804092CrossRefPubMed

13.

Rabe KF, Nair P, Brusselle G, Maspero JF, Castro M, Sher L et al (2018) Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma. N Engl J Med 378(26):2475–2485. https://doi.org/10.1056/NEJMoa1804093CrossRefPubMed

14.

Thaçi D, Simpson EL, Beck LA et al (2016) Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial. Lancet 387(10013):40–52. https://doi.org/10.1016/S0140-6736(15)00388-8CrossRefPubMed

15.

Blauvelt A, de Bruin-Weller M, Gooderham M, Cather JC, Weisman J, Pariser D et al (2017) Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. Lancet 389(10086):2287–2303CrossRefPubMed

16.

Simpson EL, Bieber T, Guttman-Yassky E, Beck LA, Blauvelt A, Cork MJ et al (2016) Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med 375(24):2335–2348. https://doi.org/10.1016/S0140-6736(17)31191-1CrossRefPubMed

17.

Wechsler ME, Ford LB, Maspero JF, Pavord ID, Papi A, Bourdin A et al (2022) Long-term safety and efficacy of dupilumab in patients with moderate-to-severe asthma (TRAVERSE): an open-label extension study. Lancet Respir Med 10(1):11–25. https://doi.org/10.1016/S2213-2600(21)00322-2CrossRefPubMed

18.

Wechsler ME, Klion AD, Paggiaro P, Nair P, Staumont-Salle D, Radwan A et al (2022) Effect of dupilumab on blood eosinophil counts in patients with asthma, chronic rhinosinusitis with nasal polyps, atopic dermatitis, or eosinophilic esophagitis. J Allergy Clin Immunol Pract 10(10):2695–2709. https://doi.org/10.1016/j.jaip.2022.05.019CrossRefPubMed

19.

von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP et al (2014) The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Int J Surg 12(12):1495–1499. https://doi.org/10.1016/j.ijsu.2014.07.013CrossRef

20.

Gevaert P, Calus L, Van Zele T, Blomme K, De Ruyck N, Bauters W et al (2013) Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma. J Allergy Clin Immunol 131(1):110–6.e1. https://doi.org/10.1016/j.jaci.2012.07.047CrossRefPubMed

21.

Linder A (1988) Symptom scores as measures of the severity of rhinitis. Clin Allergy 18(1):29–37. https://doi.org/10.1111/j.1365-2222.1988.tb02840.xCrossRefPubMed

22.

Gallo S, Russo F, Mozzanica F, Preti A, Bandi F, Costantino C et al (2020) Prognostic value of the Sinonasal Outcome Test 22 (SNOT-22) in chronic rhinosinusitis. Acta Otorhinolaryngol Ital 40(2):113–121. https://doi.org/10.14639/0392-100X-N0364CrossRefPubMedPubMedCentral

23.

Scadding G, Hellings P, Alobid I, Bachert C, Fokkens W, van Wijk RG et al (2011) Diagnostic tools in Rhinology EAACI position paper. Clin Transl Allergy 1(1):2. https://doi.org/10.1186/2045-7022-1-2CrossRefPubMedPubMedCentral

24.

Hummel T, Kobal G, Gudziol H, Mackay-Sim A (2007) Normative data for the “Sniffin’ Sticks” including tests of odor identification, odor discrimination, and olfactory thresholds: an upgrade based on a group of more than 3,000 subjects. Eur Arch Otorhinolaryngol 264(3):237–243. https://doi.org/10.1007/s00405-006-0173-0CrossRefPubMed

25.

Kuang FL (2020) Approach to patients with eosinophilia. Med Clin North Am 104(1):1–14. https://doi.org/10.1016/j.mcna.2019.08.005CrossRefPubMedPubMedCentral

26.

Hilderink JM, Klinkenberg LJJ, Aakre KM, de Wit NCJ, Henskens YMC, van der Linden N et al (2017) Within-day biological variation and hour-to-hour reference change values for hematological parameters. Clin Chem Lab Med 55(7):1013–1024. https://doi.org/10.1515/cclm-2016-0716CrossRefPubMed

27.

Caminati M, Olivieri B, Dama A, Micheletto C, Paggiaro P, Pinter P et al (2022) Dupilumab-induced hypereosinophilia: review of the literature and algorithm proposal for clinical management. Expert Rev Respir Med 16(7):713–721. https://doi.org/10.1080/17476348.2022.2090342CrossRefPubMed

28.

Chen YY, Khoury P, Ware JM, Holland-Thomas NC, Stoddard JL, Gurprasad S et al (2014) Marked and persistent eosinophilia in the absence of clinical manifestations. J Allergy Clin Immunol 133(4):1195–1202. https://doi.org/10.1016/j.jaci.2013.06.037CrossRefPubMed

29.

Helbig G, Hus M, Francuz T, Dziaczkowska-Suszek J, Soja A, Kyrcz-Krzemień S (2014) Characteristics and clinical outcome of patients with hypereosinophilia of undetermined significance. Med Oncol 31(1):815. https://doi.org/10.1007/s12032-013-0815-1CrossRefPubMed

30.

Bjerrum OW, Siersma V, Hasselbalch HC, Lind B, Andersen CL (2019) Association of the blood eosinophil count with end-organ symptoms. Ann Med Surg (Lond) 9(45):11–18. https://doi.org/10.1016/j.amsu.2019.06.015CrossRef

31.

Campisi R, Crimi C, Nolasco S, Beghè B, Antonicelli L, Guarnieri G et al (2021) Real-world experience with dupilumab in severe asthma: one-year data from an italian named patient program. J Asthma Allergy 14:575–583. https://doi.org/10.2147/JAA.S312123CrossRefPubMedPubMedCentral

32.

Dupin C, Belhadi D, Guilleminault L, Gamez AS, Berger P, De Blay F et al (2020) Effectiveness and safety of dupilumab for the treatment of severe asthma in a real-life French multi-centre adult cohort. Clin Exp Allergy 50(7):789–798. https://doi.org/10.1111/cea.13614CrossRefPubMed

33.

Renner A, Marth K, Patocka K, Idzko M, Pohl W (2021) Dupilumab rapidly improves asthma control in predominantly anti-IL5/IL5R pretreated Austrian real-life severe asthmatics. Immun Inflamm Dis 9(3):624–627. https://doi.org/10.1002/iid3.434CrossRefPubMedPubMedCentral

34.

Ferrucci S, Casazza G, Angileri L, Tavecchio S, Germiniasi F, Berti E et al (2020) Clinical response and quality of life in patients with severe atopic dermatitis treated with dupilumab: a single-center real-life experience. J Clin Med 9(3):791. https://doi.org/10.3390/jcm9030791CrossRefPubMedPubMedCentral

35.

Marcant P, Balayé P, Merhi R, Jendoubi F, Nosbaum A, Raison-Peyron N et al (2021) Dupilumab-associated hypereosinophilia in patients treated for moderate-to-severe atopic dermatitis. J Eur Acad Dermatol Venereol 35(6):e394–e396. https://doi.org/10.1111/jdv.17177CrossRefPubMed

36.

Patruno C, Napolitano M, Argenziano G, Peris K, Ortoncelli M, Girolomoni G et al (2021) Dupilumab therapy of atopic dermatitis of the elderly: a multicentre, real-life study. J Eur Acad Dermatol Venereol 35(4):958–964. https://doi.org/10.1111/jdv.17094CrossRefPubMed

37.

Fargnoli MC, Esposito M, Ferrucci S, Girolomoni G, Offidani A, Patrizi A et al (2021) Real-life experience on effectiveness and safety of dupilumab in adult patients with moderate-to-severe atopic dermatitis. J Dermatolog Treat 32(5):507–513. https://doi.org/10.1080/09546634.2019.1682503CrossRefPubMed

38.

Ahn J, Bae JY, Seo SJ (2020) A retrospective case series hypereosinophilia during dupilumab treatment: hypereosinophilia could be a pharmacogenetic biomarker of dupilumab. Dermatol Ther 33(6):e13847. https://doi.org/10.1111/dth.13847CrossRefPubMed

39.

Loperfido A, Ciofalo A, Cavaliere C, Begvarfaj E, Cascone F, Alfonzo G et al (2023) Dupilumab’s impact on blood parameters in nasal polyposis: 18-month follow-up in real life. J Immunol Res 2023:4027701. https://doi.org/10.1155/2023/4027701CrossRefPubMedPubMedCentral

40.

Rampi A, Tanzini U, Vinciguerra A, Danè G, Moroni L, Yacoub MR et al (2023) Early increase in eosinophil count may predict long-term hypereosinophilia during dupilumab treatment: a 2-year observational study. Int Forum Allergy Rhinol. https://doi.org/10.1002/alr.23212CrossRefPubMed

41.

Kemp P, van der Lans RJL, Otten JJ, Adriaensen GFJPM, Benoist LBL, Cornet ME, Hoven DR, Rinia B, Verkest V, Fokkens WJ, Reitsma S (2023) Hypereosinophilia during dupilumab treatment in patients with chronic rhinosinusitis with nasal polyps. Rhinology. https://doi.org/10.4193/Rhin23.357CrossRef

42.

Wollenberg A, Beck LA, Blauvelt A, Simpson EL, Chen Z, Chen Q et al (2020) Laboratory safety of dupilumab in moderate-to-severe atopic dermatitis: results from three phase III trials (LIBERTY AD SOLO 1, LIBERTY AD SOLO 2, LIBERTY AD CHRONOS). Br J Dermatol 182(5):1120–1135. https://doi.org/10.1111/bjd.18434CrossRefPubMed

43.

Ryser FS, Yalamanoglu A, Valaperti A, Brühlmann C, Mauthe T, Traidl S et al (2023) Dupilumab-induced eosinophilia in patients with diffuse type 2 chronic rhinosinusitis. Allergy 78(10):2712–2723. https://doi.org/10.1111/all.15844CrossRefPubMed

44.

Lommatzsch M, Stoll P, Winkler J, Zeise-Wehry D, Tronnier M, Weber MA et al (2021) Eosinophilic pleural effusion and stroke with cutaneous vasculitis: two cases of dupilumab-induced hypereosinophilia. Allergy 76(9):2920–2923. https://doi.org/10.1111/all.14964CrossRefPubMed

45.

Briegel I, Felicio-Briegel A, Mertsch P, Kneidinger N, Haubner F, Milger K (2021) Hypereosinophilia with systemic manifestations under dupilumab and possibility of dual benralizumab and dupilumab therapy in patients with asthma and CRSwNP. J Allergy Clin Immunol Pract 9(12):4477–4479. https://doi.org/10.1016/j.jaip.2021.07.049CrossRefPubMed

46.

Kimura A, Takeda A, Ikebukuro T, Hori J (2021) Serum IgE reduction and paradoxical eosinophilia associated with allergic conjunctivitis after dupilumab therapy. J Ophthalmic Inflamm Infect 11(1):3. https://doi.org/10.1186/s12348-020-00234-yCrossRefPubMedPubMedCentral

Title: Temporal trends of blood eosinophilia in severe uncontrolled CRSwNP treated with dupilumab: a real-life study
Authors: Eugenio De Corso
Claudio Montuori
Silvia Baroni
Rodolfo F. Mastrapasqua
Davide P. Porru
Leandro M. D’Auria
Giuseppe D’Agostino
Daniele Penazzi
Gabriele De Maio
Maria E. Onori
Francesca Sarlo
Marco Corbo’
Jacopo Galli
Publication date: 29-12-2023
Publisher: Springer Berlin Heidelberg
Keywords: Eosinophilia
Dupilumab
Rhinosinusitis
Published in: European Archives of Oto-Rhino-Laryngology / Issue 5/2024
Print ISSN: 0937-4477
Electronic ISSN: 1434-4726
DOI: https://doi.org/10.1007/s00405-023-08417-8

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Temporal trends of blood eosinophilia in severe uncontrolled CRSwNP treated with dupilumab: a real-life study

Abstract

Purpose

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 5/2024

Epidemiology and risk factors for extension of necrotizing otitis externa

Organization of head and neck cancer rehabilitation care: a national survey among healthcare professionals in Dutch head and neck cancer centers

Reply to Kalfert comment on “Zwierz et al. Maximal medical treatment of adenoid hypertrophy: a prospective study of preschool children”

Monocyte to high-density lipoprotein ratio as a novel-potential biomarker for predicting prognosis of Bell’s palsy

Intravascular papillary endothelial hyperplasia of the maxillary sinus extending into the contralateral nasal cavity

Comparative analysis of masseter muscle electrical activity by nasal patency in children with rhinitis and asthma: a pilot observational study